FMC-R regimen

	WikiDoc Resources for FMC-R regimen
Articles
Most recent articles on FMC-R regimen Most cited articles on FMC-R regimen Review articles on FMC-R regimen Articles on FMC-R regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on FMC-R regimen Images of FMC-R regimen Photos of FMC-R regimen Podcasts & MP3s on FMC-R regimen Videos on FMC-R regimen
Evidence Based Medicine
Cochrane Collaboration on FMC-R regimen Bandolier on FMC-R regimen TRIP on FMC-R regimen
Clinical Trials
Ongoing Trials on FMC-R regimen at Clinical Trials.gov Trial results on FMC-R regimen Clinical Trials on FMC-R regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on FMC-R regimen NICE Guidance on FMC-R regimen NHS PRODIGY Guidance FDA on FMC-R regimen CDC on FMC-R regimen
Books
Books on FMC-R regimen
News
FMC-R regimen in the news Be alerted to news on FMC-R regimen News trends on FMC-R regimen
Commentary
Blogs on FMC-R regimen
Definitions
Definitions of FMC-R regimen
Patient Resources / Community
Patient resources on FMC-R regimen Discussion groups on FMC-R regimen Patient Handouts on FMC-R regimen Directions to Hospitals Treating FMC-R regimen Risk calculators and risk factors for FMC-R regimen
Healthcare Provider Resources
Symptoms of FMC-R regimen Causes & Risk Factors for FMC-R regimen Diagnostic studies for FMC-R regimen Treatment of FMC-R regimen
Continuing Medical Education (CME)
CME Programs on FMC-R regimen
International
FMC-R regimen en Espanol FMC-R regimen en Francais
Business
FMC-R regimen in the Marketplace Patents on FMC-R regimen
Experimental / Informatics
List of terms related to FMC-R regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: FCMR regimen; FCM-R regimen; FMC-R regimen; R-FCM regimen; Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone regimen

Overview

FMC-R regimen refers to a regimen consisting of fludarabine, mitoxantrone, cyclophosphamide and rituximab, used in the treatment of resistant or relapsed chronic lymphocytic leukaemia.^[1]

Regimen

FFludarabine

MMitoxantrone

CCyclophosphamide

RRituximab

Indications

Indolent non-Hodgkin's lymphoma and relapsed or refractory mantle cell lymphoma.^[2]
CLL^[3]

References

↑ Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B; et al. (2004). "The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group". Blood. 104 (10): 3064–71. doi:10.1182/blood-2004-04-1323. PMID 15284112.
↑ "NCI Thesaurus".
↑ Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ (2010). "Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years". Leuk Res. 34 (3): 284–8. doi:10.1016/j.leukres.2009.07.008. PMID 19646755.

[pmid15284112-1] Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B; et al. (2004). "The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group". Blood. 104 (10): 3064–71. doi:10.1182/blood-2004-04-1323. PMID 15284112.

[2] "NCI Thesaurus".

[pmid19646755-3] Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ (2010). "Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years". Leuk Res. 34 (3): 284–8. doi:10.1016/j.leukres.2009.07.008. PMID 19646755.

[1]

[2]

[3]

FMC-R regimen

Overview

Regimen

Indications

References

Navigation menu